Taragarestrant meglumine

Cat. No.: HY-147402A

CAS No.: 2446618-18-2

Molecular Formula: $C_{32}H_{42}Cl_2FN_3O_7$

Molecular Weight: 670.6

Target: Estrogen Receptor/ERR

Pathway: Vitamin D Related/Nuclear Receptor

Storage: 4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 20.83 mg/mL (31.06 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.4912 mL	7.4560 mL	14.9120 mL
	5 mM	0.2982 mL	1.4912 mL	2.9824 mL
	10 mM	0.1491 mL	0.7456 mL	1.4912 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (3.10 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (3.10 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (3.10 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models[1][2].

In Vivo

Taragarestrant (D-0502) exhibits superior PK profiles suitable for clinical development[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lin WY, et, al. Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models. 2018 Jul 1;78(13):5776.

[2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA